These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 18320363)
1. The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma. Uygun K; Aksu G; Cicin I; Karagol H; Kocak Z; Fayda M; Binici A; Uzunoglu F Med Oncol; 2008; 25(4):408-14. PubMed ID: 18320363 [TBL] [Abstract][Full Text] [Related]
2. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N; Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337 [TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China. Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219 [TBL] [Abstract][Full Text] [Related]
4. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC). Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998 [TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum-based chemotherapy. Nakamura Y; Kunitoh H; Kubota K; Sekine I; Yamamoto N; Tamura T; Kodama T; Saijo N Am J Clin Oncol; 2003 Oct; 26(5):459-64. PubMed ID: 14528070 [TBL] [Abstract][Full Text] [Related]
7. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S; Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy. Lin CM; Chen CH; Chang JW; Tsao TC Am J Clin Oncol; 2009 Apr; 32(2):169-73. PubMed ID: 19307958 [TBL] [Abstract][Full Text] [Related]
9. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Pectasides D; Pectasides M; Farmakis D; Kostopoulou V; Nikolaou M; Gaglia A; Koumpou M; Mylonakis N; Xiros N; Economopoulos T; Raptis SA Ann Oncol; 2005 Feb; 16(2):294-9. PubMed ID: 15668287 [TBL] [Abstract][Full Text] [Related]
10. [Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer]. Zhang YF; Yu YF; Lu S Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1544-8. PubMed ID: 19953882 [TBL] [Abstract][Full Text] [Related]
12. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. Schneider BJ; Kalemkerian GP; Kraut MJ; Wozniak AJ; Worden FP; Smith DW; Chen W; Gadgeel SM J Thorac Oncol; 2008 Dec; 3(12):1454-9. PubMed ID: 19057272 [TBL] [Abstract][Full Text] [Related]
14. Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable non-small cell lung cancer. Kim MJ; Kim SH; Kang JH; Kim HG; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim MG; Choi JY; Lee GW Chemotherapy; 2013; 59(3):159-66. PubMed ID: 24107481 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837 [TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828 [TBL] [Abstract][Full Text] [Related]
17. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332 [TBL] [Abstract][Full Text] [Related]
18. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer. Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204 [TBL] [Abstract][Full Text] [Related]
19. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484 [TBL] [Abstract][Full Text] [Related]
20. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer. Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]